Mineralys Therapeutics, Inc. Common Stock Earnings Dividend

Mineralys Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.

Mineralys Therapeutics, Inc. Common Stock’s net profit jumped 6.8% since last year same period to $-39.34Mn in the Q1 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated -22.04% fall in its net profits since last 3-months.

Mineralys Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2026. On a quarterly growth basis, Mineralys Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a 13.83% jump from last quarter’s estimates.

Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.81.

Mineralys Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 40.51% since last year same period to -0.47 in the Q1 2026. This indicates that the Mineralys Therapeutics, Inc. Common Stock has generated 40.51% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mineralys Therapeutics, Inc. Common Stock’s return on assets (ROA) stands at -0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mineralys Therapeutics, Inc. Common Stock’s return on equity (ROE) stands at -0.31.